Canada - français - Health Canada

fresenius kabi canada ltd - adalimumab - solution - 40mg - adalimumab 40mg - disease-modifying antirheumatic agents

Canada - français - Health Canada

fresenius kabi canada ltd - adalimumab - solution - 40mg - adalimumab 40mg - disease-modifying antirheumatic agents

Canada - français - Health Canada

sandoz canada incorporated - adalimumab - solution - 20mg - adalimumab 20mg - disease-modifying antirheumatic agents

Union européenne - français - EMA (European Medicines Agency)

roche registration gmbh - pertuzumab, trastuzumab - néoplasmes du sein - agents antinéoplasiques - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

Canada - français - Health Canada

lundbeck canada inc - eptinézumab - solution - 100mg - eptinézumab 100mg - calcitonin-gene-related peptide (cgrp) antagonists

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - bevacizumabum - solution à diluer pour perfusion - bevacizumabum 100 mg, trehalosum dihydricum, natrii dihydrogenophosphas monohydricus, dinatrii phosphas, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 4 ml corresp. natrium 5.42 mg. - metastasiertes kolon- oder rektumkarzinom, metastasiertes mammakarzinom, fortgeschrittenes, metastasiertes oder rezidivierendes nicht-kleinzelliges lungenkarzinom (nsclc), fortgeschrittenes und/oder metastasierendes nierenzellkarzinom, glioblastom (who grad iv), ovarialkarzinom, zervixkarzinom - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - bevacizumabum - solution à diluer pour perfusion - bevacizumabum 400 mg, trehalosum dihydricum, natrii dihydrogenophosphas monohydricus, dinatrii phosphas, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 16 ml corresp. natrium 21.68 mg. - metastasiertes kolon- oder rektumkarzinom, metastasiertes mammakarzinom, fortgeschrittenes, metastasiertes oder rezidivierendes nicht-kleinzelliges lungenkarzinom (nsclc), fortgeschrittenes und/oder metastasierendes nierenzellkarzinom, glioblastom (who grad iv), ovarialkarzinom, zervixkarzinom - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - bevacizumabum - solution à diluer pour perfusion - bevacizumabum 100 mg, trehalosum dihydricum, natrii dihydrogenophosphas monohydricus, dinatrii phosphas, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 4 ml corresp. natrium 5.44 mg. - onkologikum - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - bevacizumabum - solution à diluer pour perfusion - bevacizumabum 400 mg, trehalosum dihydricum, natrii dihydrogenophosphas monohydricus, dinatrii phosphas, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 16 ml corresp. natrium 21.76 mg. - onkologikum - biotechnologika

Canada - français - Health Canada

abbvie corporation - risankizumab - solution - 150mg - risankizumab 150mg - misc. skin and mucous membrane agents